Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-4718 in Relapsed/Refractory AML or B-ALL
NCT02215629Phase 1Withdrawn
- Sponsor
- Verastem Oncology
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of VS-4718 in acute myeloid leukemia (AML) and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Verastem Oncology. Primary endpoints: Maximum Tolerated Dose at Day 28 and Safety and Tolerability of VS-4718 at Day 28. Status: withdrawn.
02
Drugs
VS-4718
03
Conditions
acute myeloid leukemia (AML)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02215629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215629.